Sei Investments Co. Has $52.02 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Sei Investments Co. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 7.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 222,580 shares of the medical instruments supplier’s stock after acquiring an additional 15,193 shares during the quarter. Sei Investments Co. owned approximately 0.08% of Becton, Dickinson and Company worth $52,016,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of BDX. Gryphon Financial Partners LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at about $211,000. US Bancorp DE boosted its stake in Becton, Dickinson and Company by 7.4% during the fourth quarter. US Bancorp DE now owns 82,894 shares of the medical instruments supplier’s stock worth $20,212,000 after acquiring an additional 5,678 shares in the last quarter. Team Hewins LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $295,000. Congress Wealth Management LLC DE grew its holdings in shares of Becton, Dickinson and Company by 7.9% during the fourth quarter. Congress Wealth Management LLC DE now owns 1,809 shares of the medical instruments supplier’s stock valued at $441,000 after buying an additional 133 shares during the last quarter. Finally, Hilltop Holdings Inc. bought a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $472,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $233.50 on Monday. The company’s fifty day simple moving average is $235.51 and its two-hundred day simple moving average is $235.54. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $269.52. The firm has a market cap of $67.48 billion, a PE ratio of 51.43, a price-to-earnings-growth ratio of 1.91 and a beta of 0.42. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter in the previous year, the business earned $2.96 EPS. Becton, Dickinson and Company’s revenue was up 2.3% compared to the same quarter last year. As a group, equities analysts expect that Becton, Dickinson and Company will post 13.1 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of recent analyst reports. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI lowered their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.